Lazaridis, L
2926  Ergebnisse:
Personensuche X
?
1

P11.65.B TEMPORAL MUSCLE THICKNESS AS A PROGNOSTIC MARKER I..:

Lazaridis, L ; Moenninghoff, C ; Schmidt, T...
Neuro-Oncology.  25 (2023)  Supplement_2 - p. ii89-ii90 , 2023
 
?
2

OS05.6.A TELEMEDICINE IN NEURO-ONCOLOGY - AN EVALUATION OF ..:

Feldheim, J ; Schmidt, T ; Oster, C...
Neuro-Oncology.  25 (2023)  Supplement_2 - p. ii16-ii17 , 2023
 
?
3

P15.01.A FET PET SENSITIVITY IN PRIMARY BRAIN TUMORS ACCORD..:

Oster, C ; Blau, T ; Keyvani, K...
Neuro-Oncology.  25 (2023)  Supplement_2 - p. ii109-ii109 , 2023
 
?
4

Vaginal Leiomyomas - Safe Steps for Laparoscopic removal: f..:

Giovannopoulou, E ; Kogeorgos, S ; Lazaridis, A.
Facts, Views and Vision in ObGyn.  15 (2023)  2 - p. 161-165 , 2023
 
?
5

P11.66.A COMBINATION OF TROFOSFAMIDE AND ETOPOSIDE IN RECUR..:

Schmidt, T ; Agkatsev, S ; Feldheim, J...
Neuro-Oncology.  25 (2023)  Supplement_2 - p. ii90-ii90 , 2023
 
?
6

P11.15.B First multicentric real-life experience with the c..:

Lazaridis, L ; Schmidt, T ; Agkatsev, S...
Neuro-Oncology.  24 (2022)  Supplement_2 - p. ii58-ii59 , 2022
 
?
7

Evaluation of macular function and morphology following acc..:

Dettoraki, M ; Droutsas, K ; Lazaridis, A.
European Journal of Ophthalmology.  32 (2022)  5 - p. 2547-2553 , 2022
 
?
8

OS06.5.A Investigating safety and efficacy of TTFields prio..:

Kebir, S ; Lazaridis, L ; Schmidt, T...
Neuro-Oncology.  24 (2022)  Supplement_2 - p. ii14-ii14 , 2022
 
?
9

P11.14.A Systematic review of phase III trials in newly dia..:

Oster, C ; Lazaridis, L ; Feldheim, J...
Neuro-Oncology.  24 (2022)  Supplement_2 - p. ii58-ii58 , 2022
 
?
10

P17.04.B Combination of Trofosfamide and Etoposide in Recur..:

Schmidt, T ; Agkatsev, S ; Feldheim, J...
Neuro-Oncology.  24 (2022)  Supplement_2 - p. ii89-ii89 , 2022
 
?
12

Platelet microvesicles are associated with the severity of ..:

Gkaliagkousi, E. ; Gavriilaki, E. ; Yiannaki, E....
Journal of Thrombosis and Thrombolysis.  51 (2020)  4 - p. 1138-1143 , 2020
 
?
14

P14.61 Tumor Treating Fields (TTFields) combined with lomus..:

Lazaridis, L ; Schäfer, N ; Schmidt, T...
Neuro-Oncology.  21 (2019)  Supplement_3 - p. iii81-iii81 , 2019
 
?
15

P14.62 Safety and adverse event profile post-market surveil..:

Schmidt, T ; Kebir, S ; Lazaridis, L..
Neuro-Oncology.  21 (2019)  Supplement_3 - p. iii81-iii82 , 2019
 
1-15